MA08.072o, Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use

By 11/26/2025: Billing and clinical teams must obtain and review the full text of policy MA08.072o from the provided source URL to identify specific coverage requirements, prior authorization mandates, and billing code updates for bevacizumab and related biosimilars. Update billing system rules, prior authorization workflows, and provider documentation templates as needed based on policy content. Communicate any changes to oncology providers and front-desk staff. Failure to implement required prior authorizations may result in claim denials for bevacizumab administrations.